Horn R. Lawrence Van purchases 1,860 shares of Harrow Health, Inc. (NASDAQ:HROW).
On December 22, Harrow Health, Inc. Director Horn R. Lawrence Van purchased 1,860 shares of the company’s stock. Harrow Health, Inc. is traded on the NASDAQ under the ticker symbol HROW. The total cost of purchasing the stock was $24,961.20, which comes from an average price of $13.42 per share. The director is now the direct owner of 1,860 of the company’s shares, which have a value of $24,961.20 following the completion of the transaction. By following the link, which will take you to a legal file submitted to the SEC, you will have the opportunity to obtain additional information regarding the acquisition.
A number of the world’s largest investors have made recent adjustments to the quantity of HROW stock that each of them owns. During the third quarter, Tower Research Capital LLC (TRC) increased the number of Harrow Health shares owned by a factor of 530.7 percent. Tower Research Capital LLC (TRC) has a total of 2,756 shares of the company’s stock, worth $33,000, after purchasing an additional 2,319 shares throughout the most recent period. These shares were acquired through the purchase of additional lots. During the third quarter, Barclays PLC achieved a 44.3% increase in the proportion of Harrow Health stock it owned. Barclays PLC now holds 3,560 shares of the company’s stock following the acquisition of an additional 1,093 shares during the most recent period. Each share of the company’s stock is currently valued at $43,000. To fill a newly created position in Harrow Health during the second quarter, Captrust Financial Advisors invested approximately 51,000 dollars into the company. Envestnet Asset Management Inc. made a new investment in Harrow Health during the first quarter, and their investment was around $70,000. The most recent deal was closed during the second quarter when Cubist Systematic Strategies LLC shelled out close to $78,000 to acquire a new investment in Harrow Health. This was the most recent transaction that was completed. Institutional investors hold 56.47 percent of the total shares of the company.
On Friday, the price of a single share of NASDAQ HROW stock was set at $13.49 when trading got underway. According to the simple moving average calculated over the past 200 days, the stock’s current price is $9.44, while the simple moving average calculated over the past 50 days puts it at $11.68. A debt-to-equity ratio comes in at 83.80; a quick ratio comes in at 3.20; a current ratio comes in at 3.49, and a quick ratio comes in at 3.49. Harrow Health, Inc. hit a low point over the past year of its stock price of $5.40, while the company reached a high point over the past year of $13.90. The company has a beta value of 0.36 and a market capitalization of 365.17 million dollars. Its price-to-earnings ratio is -16.25. On Thursday, September 8, B. Riley released a research note stating it would begin covering shares of Harrow Health. They recommended that the company “buy” the stock and establish a price objective of $17.00.
Ophthalmology is a primary area of concentration for Harrow Health, Inc., a medical service provider specializing in the field of ophthalmology. This company owns the pharmaceutical compounding and outsourcing business known as ImprimisRx. ImprimisRx focuses on ophthalmology-related treatments. In addition, surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that specializes in the development and commercialization of therapeutics for ocular surface diseases, and Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that specializes in the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in the hospital, outpatient, and ambulatory settings, also hold equity interests in the company. Surface Ophthalmics, Inc. was founded in Surface Ophthalmics and is primarily concerned with the creation.
Source link Google News